CoChat

Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance

Open access
Vendrell, Joan, El Bekay, Rajaa, Peral, Belén, García-Fuentes, Eduardo, Megia, Anna, Macias-Gonzalez, Manuel, Real, José Fernández, Jimenez-Gomez, Yolanda, Escoté, Xavier, Pachón, Gisela, Simó, Rafael, Selva, David M., Malagón, María M., Tinahones, Francisco J. · 2011 · Endocrinology

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

The increase in glucagon-like peptide-1 (GLP-1) activity has emerged as a useful therapeutic tool for the treatment of type 2 diabetes mellitus. The actions of GLP-1 on β-cells and the nervous and digestive systems are well known. The action of this peptide in adipose tissue (AT), however, is still poorly defined. Furthermore, no relationship has been established between GLP-1 receptor (GLP-1R) in AT and obesity and insulin resistance (IR). We provide evidence for the presence of this receptor in AT and show that its mRNA and protein expressions are increased in visceral adipose depots from morbidly obese patients with a high degree of IR. Experiments with the 3T3-L1 cell line showed the lipolytic and lipogenic dose-dependent effect of GLP-1. Moreover, GLP-1 stimulated lipolysis in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate cyclase/cAMP signaling. Our data also demonstrate that the expression of the GLP-1R in AT correlated positively with the homeostasis model assessment index in obese IR subjects. Furthermore, prospective studies carried out with patients that underwent biliopancreatic diversion surgery showed that subjects with high levels of GLP-1R expression in AT, which indicates a deficit of GLP-1 in this tissue, were those whose insulin sensitivity improved after surgery, suggesting the potential relationship between AT GLP-1R and insulin sensitivity amelioration in obese subjects. Altogether these results indicate that the GLP-1/GLP-1R system in AT represents another potential candidate for improving insulin sensitivity in obese patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2011-1070

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

  • Glucagon-like peptide 1 (GLP-1)

    Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868

    “These recent studies include the finding of the receptor in differentiating mouse 3T3-L1 pre-adipocytes [382e384], adipocytes formed from human bone marrow-derived mesenchymal stem cells [385], human epicardial fat [386], and in human visceral white adipose tissue [387].”
    Background
  • Pharmacology, physiology, and mechanisms of incretin hormone action.

    Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500

    “GLP-1 (10–100 nM, 4 hr) increased lipolytic rates in human primary adipocytes in vitro (Vendrell et al., 2011).”
    Background
  • Trends in insulin resistance: insights into mechanisms and therapeutic strategy

    Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939

    “For example, (1) Glucagon-like peptide 1 (GLP1) is an intestinal hormone that can enhance insulin secretion in a glucosedependent manner by activating the GLP-1 receptor (GLP-1R) that is highly expressed on islet β cells.(462,463) GLP-1 receptor agonists including Liraglutide, Semaglutide, Dulaglutide and Exenatide ha…”
    Background
  • Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

    Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456

    “Interestingly, Vendell and colleagues reported that GLP-1R expression (mRNA, protein) is greatest in adipocytes isolated from patients with morbid obesity and in particular, IR [35].”
    Background
  • Regulation of adipocyte lipolysis

    Frühbeck, G., Méndez-Giménez, L., Fernández-Formoso, J.-A., Fernández, S., & Rodríguez, A. (2014) · Nutrition Research Reviews · doi:10.1017/s095442241400002x · Cited by 429

    “A dose-dependent lipolytic effect of GLP-1 in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate cyclase/cAMP signalling has been shown((83)).”

See all 173

Metadata

Authors
Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., Simó, R., Selva, D. M., Malagón, M. M., & Tinahones, F. J.
Affiliations
  • Instituto de Salud Carlos III (ES)
  • University Hospital of Tarragona Joan XXIII (J.V., A.M., X.E., G.P.), IISPV, Rovira i Virgili University, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, 43007 Tarragona, Spain
  • Consejo Superior de Investigaciones Científicas (ES)
  • Laboratorio de Investigación Biomédica (R.E.B., E.G.-F., M.G., Y.J.-G., F.J.T.), Hospital Virgen de la Victoria, 29010 Málaga, Spain
  • Department of Cell Biology, Physiology, and Immunology (Y.J.-G., M.M.M.), Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CB06/03/0020) and Instituto de Salud Carlos III, Instituto de Investigación Biomédica, University of Córdoba, 14004 Córdoba, Spain
  • Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
Venue
Endocrinology
Published
2011-08-23
Volume
152
Issue
11
Pages
4072-4079
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2143149722
Cited by
173
References
28
Citations by year
2026: 13 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 11 · 2021: 11 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 12 · 2013: 11 · 2012: 5
FWCI
6.72
Type
journal article
Language
en
Open access
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
Funders
  • Ministerio de Ciencia e Innovación (SAF-2009-10461)
  • Servicio Andaluz de Salud
  • Instituto de Salud Carlos III (PS09/00997, PI070953)
  • European Regional Development Fund
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
GLP-1 receptor, adipose tissue, obesity, insulin resistance, lipolysis, lipogenesis, 3T3-L1 adipocytes, biliopancreatic diversion, insulin sensitivity, visceral adipose tissue, type 2 diabetes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Adipose Tissue, Animals, Cells, Cultured, Humans, Insulin Resistance, Obesity, Morbid, Prospective Studies, Adipocytes, Receptors, Glucagon, 3T3-L1 Cells, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.